Unknown

Dataset Information

0

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.


ABSTRACT: BACKGROUND:OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without allodynia. METHODS:Patients (n?=?715) were treated with onabotulinumtoxinA 155?U every 12?weeks for 9 treatment cycles. The Allodynia Symptom Checklist was used to identify patients with allodynia (scores ?3). The primary outcome for this subanalysis was reduction in monthly headache days from baseline for weeks 105 to 108 in groups with and without allodynia. Other outcomes included assessments of moderate to severe headache days, disability (using the Migraine Disability Assessment [MIDAS] questionnaire), and health-related quality of life (Migraine-Specific Quality-of-Life Questionnaire [MSQ] v2). Adverse events and their relation to treatment were recorded. RESULTS:OnabotulinumtoxinA was associated with a significant mean (SD) reduction in headache day frequency at week 108 relative to baseline in patients with (n?=?289) and without (n?=?426) allodynia (-?10.8 [7.1] and?-?12.5 [7.4], respectively; both P?

SUBMITTER: Young WB 

PROVIDER: S-EPMC6734222 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.

Young William B WB   Ivan Lopez J J   Rothrock John F JF   Orejudos Amelia A   Manack Adams Aubrey A   Lipton Richard B RB   Blumenfeld Andrew M AM  

The journal of headache and pain 20190122 1


<h4>Background</h4>OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without allodynia.<h4>Methods</h4>Patients (n = 715) were treated with onabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles. The Allodynia Symptom Checklist was  ...[more]

Similar Datasets

| S-EPMC6734507 | biostudies-literature
| S-EPMC6647876 | biostudies-literature
| S-EPMC5799088 | biostudies-literature
| S-EPMC10652784 | biostudies-literature
| S-EPMC6978557 | biostudies-literature
| S-EPMC7666298 | biostudies-literature
| S-EPMC4114914 | biostudies-literature
| S-EPMC10399003 | biostudies-literature
| S-EPMC7687094 | biostudies-literature
| S-EPMC4489131 | biostudies-literature